Greenland Technologies Holding Corp (GTEC): GTEC READY TO RUMBLE

Play Episode

6min

Proactive - Interviews for investors

Race Oncology’s RC220 trial gets green light

Race Oncology Ltd chair Peter Smith talked with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with its clinical trial for RC220, a new formulation of bisantrene. Smith explained that the trial aims to establish the safety of RC220 both as a standalone treatment and in combination with doxorubicin, a commonly used chemotherapy drug. "What we’ll be seeking to achieve is establishing the maximum tolerated dose for the combination of the two drugs together," he said. The study will also investigate whether RC220 can reduce doxorubicin’s known toxicity to the cardiovascular system. Smith highlighted that doxorubicin can cause permanent heart damage, potentially reducing patient lifespan by the equivalent of a decade. The company aims to demonstrate that RC220 can enhance anti-cancer effects while mitigating heart-related side effects. The trial will be conducted in multiple phases, beginning in Australia, with expansion planned into Korea and Hong Kong later in the year. Smith noted that the Cancer Care Foundation is playing a role in patient support and accessibility. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future updates. #RaceOncology #CancerResearch #ClinicalTrial #Biotech #Oncology #RC220 #Doxorubicin #CardioProtection #Pharma #MedicalResearch #CancerTreatment

Proactive - Interviews for investors

Sona Nanotech CMO discusses THT's potential to enhance immunotherapy efficacy

Sona Nanotech Inc chief medical officer Dr Carman Giacomantonio takes Proactive's Stephen Gunnion through the company’s latest findings related to its targeted hyperthermia therapy (THT), which he described as showing “very enabling immunogenic” effects in recent experiments. The THT platform works by delivering controlled heat to the core of a tumour, triggering a natural cell death response and activating the body's immune system. Giacomantonio explained that this process exposes tumour proteins to immune cells, increasing the chance that they will be recognised and attacked. He noted that “all cancer cells have this kind of evolutionary quality” of resisting cell death, but THT stresses the cells enough to induce it. These latest experiments build on data first shared in December, with increased sample sizes confirming the reproducibility of the results. According to Giacomantonio, tumours treated with saline or checkpoint inhibitors alone continued to grow, while those exposed to THT and the immune modulator PD1 showed complete inhibition or reduction in growth. Looking ahead, he said the company plans to expand testing to demonstrate systemic immune responses, with the goal of treating metastatic cancers by targeting a single tumour site. Visit Proactive's YouTube channel for more company updates. Don’t forget to give this video a like, subscribe to the channel, and enable notifications so you never miss future content. #SonaNanotech #CancerTherapy #TargetedHyperthermia #Immunotherapy #BiotechNews #TumourTreatment #CancerResearch #MedicalInnovation #PD1Inhibitor #MetastaticCancer #HealthcareTech #OncologyBreakthrough

Proactive - Interviews for investors

St George Mining’s dual track growth plan

St George Mining Ltd executive chairman John Prineas talked with Kerry Stevenson at Proactive about the company's recent acquisition of the Araxá niobium and rare earths project in Brazil. The deal, completed in February, provides St George with an advanced-stage project with high-grade niobium and rare earth elements. Prineas highlighted niobium’s strategic importance, noting that it is primarily used to strengthen steel, with additional applications in medical technology, batteries, and defence. He emphasised the commodity's stable pricing due to limited global supply. The company secured A$20 million in funding to advance the project and is preparing a JORC-compliant mineral resource estimate, expected in the coming weeks. The existing data, based on historical drilling, indicates a 20-year mine life and a US$956 million NPV under a previous non-JORC study. St George aims to optimise the project for niobium, conduct further drilling, and expand the resource. Prineas also addressed Brazil's mining jurisdiction, highlighting strong government support and agreements to expedite approvals. The company is pursuing a dual-track strategy, progressing toward development while ramping up exploration drilling to expand the resource base. Stay tuned for more updates! Visit Proactive's YouTube channel for more interviews, and don’t forget to like, subscribe, and turn on notifications. #StGeorgeMining #ASXSGQ #Niobium #RareEarths #MiningStocks #JORC #BrazilMining #CriticalMetals #ResourceInvestment #BatteryMetals

Proactive - Interviews for investors

Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth

Protalix BioTherapeutics Chairman Dr Eliot Forster joined Steve Darling from Proactive to discuss the company’s innovative approach to drug manufacturing, which leverages plant cells instead of traditional mammalian cells. This unique method enhances purity, sustainability, and reproducibility, setting Protalix apart in the biotech industry. Forster highlighted the company's commercial success, noting that Protalix has two marketed products through partnerships with Pfizer and Chiesi. He emphasized the company’s strong financial position, having repaid all outstanding debt and operating without warrants, reinforcing its ability to drive long-term growth. A key focus of the discussion was PRX-115, Protalix’s experimental treatment for severe gout. In 2024, the company completed a first-in-human study with promising results. A Phase 2 trial is scheduled for 2025, and Forster expressed optimism about its potential to address a significant unmet medical need. Beyond PRX-115, Forster detailed the company’s strong financial performance in 2024, describing it as a breakthrough year fueled by increased revenue from its three business streams. Looking ahead, Protalix is actively advancing treatments for rare diseases, including renal conditions, as it continues to expand its innovative pipeline. #proactiveinvestors #protalixbiotherapeutics #nyseamerican #plx #Biotech #DrugDevelopment #GoutTreatment #Pharmaceuticals #EliotForster #PRX115 #HealthcareInnovation #ProactiveInvestors

Followers	867
Posts	35411
Boards Moderated	18
Alias Born	03/22/2016

Volume:	1,967,740
Day Range:	1.67 - 1.9259
Bid:	1.71
Ask:	1.77
Last Trade Time:	7:59:55 PM EDT
Total Trades:	7,859

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

GTEC Detailed Quote

Recent GTEC News

More GTEC News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent GTEC News

Go Ad-Free